Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2025 07:30 ET | Source: PolyPid Ltd.

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key...
June 06, 2025 16:05 ET | Source: PolyPid Ltd.

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
May 20, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate...
May 14, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory...
April 29, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
April 22, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid to Participate in The Citizens Life Sciences Conference

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
March 11, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
March 03, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid to Participate in the 37th Annual ROTH Conference

PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
February 12, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in...
January 30, 2025 07:00 ET | Source: PolyPid Ltd.

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...